Lumendi Achieves Key Milestone with Completion of DiLumen EZ¹ Customer Evaluations, Setting the Stage for the Next Phase of DiLumen Product Innovation

Lumendi, a pioneering manufacturer of endosurgical solutions, today announced the successful completion of customer evaluations of its DiLumen EZ¹, the U.S. Food and Drug Administration (FDA) 510(k)-cleared, single-use, disposable endotherapy device for procedures such as endoscopic mucosal resections (EMR) and difficult colonoscopies, and the newest addition to the company’s DiLumen suite of products. This milestone is indicative of the company’s consistent growth and innovation.

Peter Johann, Chief Executive Officer of Lumendi, noted, “Our products are designed to provide an edge in tackling the complexities of polypectomies, thereby improving patient outcomes and delivering higher curative rates. That said, the positive customer response to the DiLumen EZ¹ is a testament to our commitment, and our ability to deliver transformative solutions for challenging gastrointestinal interventions.”

The DiLumen EZ¹ is the first in a series of planned, strategic product additions and Lumendi is currently starting the evaluation phase of a second, FDA 510(k)-cleared product, the DiLumen C1. This next-generation solution is designed to facilitate complex polyp procedures in the colon and rectum, such as endoscopic submucosal dissection (ESD). This aligns with Lumendi’s vision of integrating robotic-like tools into complex GI procedures, with the aim of mainstreaming these interventions and accelerating the learning curve of advanced GI practitioners.

“By continuously expanding our product portfolio, we move closer to becoming the partner of choice for GI practitioners dealing with complex polypectomies,” Dr. Johann stated. “This includes offering the EZ-Glide, our versatile solution for lower bowel procedures, suitable for most polypectomy interventions, which has been commercially available in the U.S., EU, the UK and Asia since 2017.”

Dr. Stavros Stavropoulos, Chief of Endoscopy and Director of the program in Advanced Gastrointestinal Endoscopy and Endoscopic Surgery at Archbold Medical Center, and a key opinion leader in the field, added, “As a physician dedicated to the development and introduction of cutting-edge, advanced endoscopic surgery technologies, I believe that Lumendi’s suite of DiLumen devices represent an important advancement in the field. With increasing adoption over time, they hold the potential to drive a shift away from more invasive surgery toward minimally invasive endoluminal procedures. This should lower complication rates, require little to no hospital stay and significantly reduce recovery times for patients.”


Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy